Coloplast and OPKO Health Compared: Which is the Better Buy?

A critical review of the two medical companies' financials, operations, and market performance.

Published on Feb. 9, 2026

Got story updates? Submit your updates here. ›

OPKO Health (NASDAQ:OPK) and Coloplast A/S (OTCMKTS:CLPBY) are both medical companies, but an analysis shows OPKO Health may be the superior investment. The companies were compared across factors like dividends, valuation, risk, profitability, analyst recommendations, earnings, and institutional ownership. OPKO Health has stronger consensus ratings from analysts and higher potential upside, while Coloplast has higher revenue and earnings. OPKO Health also has more volatile stock price movements compared to the broader market.

Why it matters

This analysis provides investors with a detailed comparison of two prominent medical companies, helping them make a more informed decision about which stock may be the better long-term investment option based on the companies' fundamentals and market performance.

The details

The analysis found that OPKO Health has stronger institutional and insider ownership, indicating greater confidence from large investors. While Coloplast has higher revenue and earnings, OPKO Health is trading at a lower price-to-earnings ratio, making it more affordable. Analysts also have a stronger consensus rating and higher price target for OPKO Health compared to Coloplast. However, OPKO Health's stock is also more volatile, with a beta of 1.47 compared to Coloplast's 0.26.

  • The analysis was published on February 9, 2026.

The players

OPKO Health, Inc.

A healthcare company engaged in diagnostics and pharmaceuticals businesses internationally.

Coloplast A/S

A Danish medical device company that develops and sells intimate healthcare products and services globally.

Got photos? Submit your photos here. ›

The takeaway

This analysis suggests that OPKO Health may be the more attractive investment option compared to Coloplast A/S, based on its stronger analyst ratings, higher potential upside, and more affordable valuation, despite its more volatile stock price movements. Investors should continue to monitor the performance and developments of both companies to make the best investment decision.